OSI-027

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameOSI-027
Drug Alias NameOSI-027CERC-006ASP-7486AEVI-006AVTX-006
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsSolid tumoursLymphatic AbnormalitiesLymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAstellas Pharma Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAevi Genomic MedicineAstellas Pharma IncAvalo Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursLymphatic AbnormalitiesLymphoma

Other Information

ATC CodeN/A
Related LinksN/A